| Open Document File Size: 3,19 MBShare Result on Facebook
Company AEs / AMP / / Country United States / / Currency pence / / Event FDA Phase / Reorganization / / Facility Laboratory Findings / / IndustryTerm treatment of HIV disease / Treatment of HIV / / MedicalCondition pediatric HIV disease / HIV / hypercholesterolemia / hemolytic anemia / infectious complications / nausea / common pediatric infections / adult HIV disease / HIV RNA / onset diabetes / also opportunistic infections / diarrhea / Pediatric HIV Infection / sinus bradycardia / gastrointestinal disorders / hemophilia / lipodystrophy / degree AV block / disease / hypertriglyceridemia / hyperglycemia / Pediatric Human Immunodeficiency Virus Infection / hyperlipidemia / viremia / vomiting / lactic acidosis / pancreatitis / infection / rash / rash / fat redistribution / HIV disease / / MedicalTreatment Antiretroviral Therapy / HAART / / Organization U.S. Securities and Exchange Commission / Drug Interactions / and DOSAGE AND ADMINISTRATION / Advisory Committee / / Person Kirk M. Chan-Tack / / Position Secretary / / Product Fortovase / efavirenz / Emtriva / Zidovudine / Videx / Aptivus / Agenerase / Intelence / ranitidine / Norvir / Retrovir / Rescriptor / Sustiva / Epivir / omeprazole / Ziagen / Hivid / Invirase / Lexiva / Crixivan / Antiretroviral / Fuzeon / Prezista / Viracept / Zerit / nevirapine / Viramune / Abacavir / Lamivudine / Isentress / Viread / Didanosine / Kaletra / Selzentry / Reyataz / Stavudine / PRECAUTIONS / Kaletra tablets / SE5 / HIV-1 / SE-014 / Antiretrovirals Drug / RTV / SE-003 / SE5-022 / Kaletra tablet / Kaletra capsules / LPV/r / / ProvinceOrState Indiana / / Technology AV / Pharmacokinetics / Pharmacodynamics / / URL http /
SocialTag |
CLINICAL REVIEW Application Type[removed]Submission Number 022 Submission Code SE5